Qualigen Therapeutics (QLGN)
(Delayed Data from NSDQ)
$1.76 USD
-0.14 (-7.37%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.76 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
QLGN 1.76 -0.14(-7.37%)
Will QLGN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for QLGN based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for QLGN
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible ...
Qualigen Therapeutics (QLGN) Secures Nasdaq Compliance with Strategic Steps
Qualigen regains Nasdaq equity compliance after $4.5M private placement
Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status | ...
Qualigen Therapeutics provides update on Nasdaq listing status